ArticleClinical and experimental nephrology2026
Association between ABCG2 transporter functionality and CKD progression: a retrospective cohort study in patients with CKD stage G3.
Article in Clinical and experimental nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundATP-binding cassette subfamily G member 2 (ABCG2), an efflux transporter for urate and uremic toxins, plays a critical role in extra-renal urate elimination. Its dysfunction leads to elevated serum urate (SU) levels and may promote renal tubular urate overload and uremic toxin accumulation, potentially contributing to chronic kidney disease (CKD) progression.
methodsThis retrospective cohort study included 317 patients with CKD stage G3, with 8,664 medical records (mean 6.74-year follow-up). ABCG2 function was estimated based on genotypes for p.Q126X and p.Q141K in the ABCG2 coding region: full function, mild dysfunction (approximately 75% function), and severe dysfunction (≤ 50% function). We performed generalized estimating equation analysis to assess the estimated glomerular filtration rate (eGFR) slope and Cox regression analysis to evaluate a > 30% decline in eGFR. The models were adjusted for age, sex, CKD etiology, renin-angiotensin system inhibitor use, proteinuria, and either CKD stage (G3a/G3b) or baseline eGFR, respectively.
resultsOwing to ongoing therapeutic interventions, no significant differences in SU levels were observed among ABCG2 functional groups at baseline. The eGFR slopes for fully functional, mildly dysfunctional, and severely dysfunctional ABCG2 were - 0.95 ± 0.12, - 0.94 ± 0.16, and - 1.37 ± 0.14 mL/min/1.73 m
conclusionABCG2 functionality is associated with renal prognosis in CKD and could be a useful marker for risk stratification in clinical settings.
Indexed as
Identifiers
42801416What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.